Aggiornamento fonte cinese
With all due respect, kintor is facing a huge dilemma at present. Because of its development of COVID-19 specific drugs, it is very short of funds, so it has to make two allotments of shares within half a year. At the same time of these two allotments, their chairman of the board is also constantly reducing his holdings of kintor shares, so the outside world is speculating that COVID-19 specific drugs developed by kintor cannot be successfully listed. Now people who have bought kintor shares are abusing kintor, In addition, the share price of kintor is also declining, and the trading volume is very small. Investors have lost confidence in kintor. They feel that kintor is a dishonest enterprise. In short, kintor is now facing a huge dilemma, and they don't know whether they can continue to develop the KX-826 and GT20029.
With all due respect, kintor is facing a huge dilemma at present. Because of its development of COVID-19 specific drugs, it is very short of funds, so it has to make two allotments of shares within half a year. At the same time of these two allotments, their chairman of the board is also constantly reducing his holdings of kintor shares, so the outside world is speculating that COVID-19 specific drugs developed by kintor cannot be successfully listed. Now people who have bought kintor shares are abusing kintor, In addition, the share price of kintor is also declining, and the trading volume is very small. Investors have lost confidence in kintor. They feel that kintor is a dishonest enterprise. In short, kintor is now facing a huge dilemma, and they don't know whether they can continue to develop the KX-826 and GT20029.